ICU Medical (ICUI)
(Delayed Data from NSDQ)
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum B VGM
Zacks News
Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice
by Zacks Equity Research
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ICU Medical (ICUI) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 11.66% and 6.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why ICU Medical (ICUI) Is a Great Growth Stock
by Zacks Equity Research
ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.
ICU Medical (ICUI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 15.64% and 6.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Sep 9, 2021
by Zacks Equity Research
Companies In The News Are: COIN, TSLA, SPB, ICUI
ICU Medical (ICUI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 14.63% and 5.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 5.88% and 4.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 48.44% and 13.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q3 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
ICU Medical (ICUI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
Buy These 5 Stocks on New Analyst Coverage Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
by Zacks Equity Research
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
New Analyst Coverage Brings 5 Stocks in Focus Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
ResMed (RMD) Grows on SaaS Capabilities Amid Rising Expenses
by Zacks Equity Research
Within SaaS, ResMed (RMD) registers growing momentum in the Brightree service portfolio.
Steady Global Growth, Product Launches Aid Hill-Rom Business
by Zacks Equity Research
Hill-Rom (HRC) holds an encouraging 2022 outlook in terms of product launches.
ICU Medical (ICUI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 19.75% and 6.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?